These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30256905)

  • 1. The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial.
    Schmader KE; Levin MJ; Grupping K; Matthews S; Butuk D; Chen M; Idrissi ME; Fissette LA; Fogarty C; Hartley P; Klein NP; Nevarez M; Uusinarkaus K; Oostvogels L; Curran D
    J Gerontol A Biol Sci Med Sci; 2019 Jul; 74(8):1217-1224. PubMed ID: 30256905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults.
    Schmader KE; Levin MJ; Chen M; Matthews S; Riley ME; Woo W; Hervé C; Grupping K; Schuind AE; Oostvogels L; Curran D
    J Gerontol A Biol Sci Med Sci; 2021 Feb; 76(3):485-490. PubMed ID: 32530462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
    López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
    Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
    Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
    J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccines for preventing herpes zoster in older adults.
    de Oliveira Gomes J; Gagliardi AM; Andriolo BN; Torloni MR; Andriolo RB; Puga MEDS; Canteiro Cruz E
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD008858. PubMed ID: 37781954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
    Tavares-Da-Silva F; Co MM; Dessart C; Hervé C; López-Fauqued M; Mahaux O; Van Holle L; Stegmann JU
    Vaccine; 2020 Apr; 38(18):3489-3500. PubMed ID: 31818534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial.
    Maréchal C; Lal H; Poder A; Ferguson M; Enweonye I; Heineman TC; Hervé C; Rheault P; Talli J; Wauters D; Oostvogels L
    Vaccine; 2018 Jul; 36(29):4278-4286. PubMed ID: 29903674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
    Hesse EM; Shimabukuro TT; Su JR; Hibbs BF; Dooling KL; Goud R; Lewis P; Ng CS; Cano MV
    MMWR Morb Mortal Wkly Rep; 2019 Feb; 68(4):91-94. PubMed ID: 30703077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older.
    Curran D; Oostvogels L; Heineman T; Matthews S; McElhaney J; McNeil S; Diez-Domingo J; Lal H; Andrews C; Athan E; Berglund J; Campora L; de Looze F; Korhonen T; Leung E; Levin M; Volpi A; Johnson RW;
    J Gerontol A Biol Sci Med Sci; 2019 Jul; 74(8):1231-1238. PubMed ID: 29955836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged ≥50 years: A randomized trial.
    Min JY; Mwakingwe-Omari A; Riley M; Molo LY; Soni J; Girard G; Danier J
    J Infect; 2022 Apr; 84(4):490-498. PubMed ID: 34963639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance.
    Fiore J; Co-van der Mee MM; Maldonado A; Glasser L; Watson P
    Ther Adv Vaccines Immunother; 2021; 9():25151355211057479. PubMed ID: 35005428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.
    Vink P; Ramon Torrell JM; Sanchez Fructuoso A; Kim SJ; Kim SI; Zaltzman J; Ortiz F; Campistol Plana JM; Fernandez Rodriguez AM; Rebollo Rodrigo H; Campins Marti M; Perez R; González Roncero FM; Kumar D; Chiang YJ; Doucette K; Pipeleers L; Agüera Morales ML; Rodriguez-Ferrero ML; Secchi A; McNeil SA; Campora L; Di Paolo E; El Idrissi M; López-Fauqued M; Salaun B; Heineman TC; Oostvogels L;
    Clin Infect Dis; 2020 Jan; 70(2):181-190. PubMed ID: 30843046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.